XML 61 R51.htm IDEA: XBRL DOCUMENT
v3.24.3

Significant agreements - Novartis Collaboration Agreement - Accounting Analysis (Details) - Novartis $ in Thousands | Mar. 27, 2023 USD ($) item
--- | ---
Significant agreements. |
Transaction price | $ 50,000
Two combined performance obligations for the first and second targets comprised of the Novartis Research License and the related research and development services during the research term for the first and second targets |
Significant agreements. |
Combined performance obligations | item | 2
Transaction price | $ 18,008
Two material rights associated with limited substitution rights |
Significant agreements. |
Number of material rights | item | 2
Transaction price | $ 2,466
Two material rights associated with options to progress development candidates incorporating radionuclides |
Significant agreements. |
Number of material rights | item | 2
Transaction price | $ 19,684
Two material rights associated with options to progress development candidates not incorporating radionuclides |
Significant agreements. |
Number of material rights | item | 2
Transaction price | $ 9,842

X
- Definition The number of combined performance obligations. + References No definition available. + Details
Name: | bcyc_NumberOfCombinedPerformanceObligations
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of material rights usually associated with an option. + References No definition available. + Details
Name: | bcyc_NumberOfMaterialRights
Namespace Prefix: | bcyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allocated determined transaction price under revenue recognition arrangement. + References No definition available. + Details
Name: | bcyc_RevenueRecognitionAllocatedDeterminedTransactionPrice
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoCombinedPerformanceObligationsForFirstAndSecondTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithLimitedSubstitutionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesIncorporatingRadionuclidesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcyc_TwoMaterialRightsAssociatedWithOptionsToProgressDevelopmentCandidatesNotIncorporatingRadionuclidesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |